Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first phase 3 trial for treatment of type 2 diabetes: Indianapolis Friday, March 20, ...
In a Robinson-Patman Act (RPA)-related dispute between the manufacturer and wholesalers of Clear Eyes, a brand of eye drops, the U.S. Court of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results